Condition category
Circulatory System
Date applied
31/10/2007
Date assigned
06/11/2007
Last edited
06/11/2007
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Prof Hans Wilhelm Hoepp

ORCID ID

Contact details

Kerpener Str. 62
Cologne
50937
Germany
hw.hoepp@uni-koeln.de

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

3

Study information

Scientific title

Acronym

HEP III

Study hypothesis

Innovative ways for dissemination of guidelines are superior to traditional ways.

Ethics approval

All participants took part voluntarily and the interventions were optional therefore ethics approval was not necessary.

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Quality of life

Patient information sheet

Condition

Hypertension

Intervention

1. Guideline in print
2. Interactive guideline
3. Expert seminars
4. Control group

The intervention groups were 3825 physicians for the expert seminars and always 1500 for the guideline in print, the interactive guideline and the control group. The medium follow-up time after intervention was approximately six months.

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

Difference in guideline awareness between trained physicians and the control group.

Secondary outcome measures

Overall guideline awareness.

Overall trial start date

01/01/2004

Overall trial end date

31/03/2005

Reason abandoned

Eligibility

Participant inclusion criteria

Participants of HEP I-trial: In the HEP-I trial we explored the guideline awareness of 24899 German physicians, including all internists, cardiologists and 22% of general practitioners in a nationwide survey. The data is already published (see http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=11677375)

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

8325

Participant exclusion criteria

See inclusion criteria.

Recruitment start date

01/01/2004

Recruitment end date

31/03/2005

Locations

Countries of recruitment

Germany

Trial participating centre

Kerpener Str. 62
Cologne
50937
Germany

Sponsor information

Organisation

University of Cologne (Germany)

Sponsor details

Koeln Fortune Program
Faculty of Medicine
Kerpener Str. 62
Cologne
50937
Germany
t.hensler@uni-koeln.de

Sponsor type

University/education

Website

http://www.uni-koeln.de/index.e.html

Funders

Funder type

University/education

Funder name

University of Cologne (Germany) - Koeln Fortune Program, Faculty of Medicine

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes